Last edition
News about "OncoC4 Inc."
US FDA Grants Fast Track Designation to OncoC4's Cesalatamig
US FDA grants Fast Track Designation to OncoC4’s cesalatamig for patients with NSCLC whose disease has progressed following PD-(L)1-targeted immunotherapy and platinum-based chemotherapy.
OncoC4 Inc | 17/09/2026 | By News Bureau
OncoC4 Doses First Patient in Phase 1 Trial of ONC-783 T-Cell Engager
OncoC4 has dosed the first patient in its Phase 1 ONC-783-001 trial, evaluating the investigational T-cell engager ONC-783, developed to target the cancer-specific neoCD24 epitope in patients with advanced solid tumours.
OncoC4 Inc. | 18/08/2026 | By News Bureau | 103
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy